Nanjing Leads Biolabs (SEHK:9887) has drawn investor attention after its latest close at HK$45.16, with the share price down over the past day, week, month, and past 3 months.
Recent trading has been weak for Nanjing Leads Biolabs, with the share price return down 28.66% over the past 30 days and the 1-year total shareholder return falling 38.05%. This suggests momentum has faded as investors reassess both growth potential and risk around its clinical-stage pipeline.
Reassess Nanjing Leads Biolabs in context by scanning a curated 620 high quality undiscovered gems that could be stepping into the spotlight as attention shifts across high growth pipelines.
Nanjing Leads Biolabs has a busy clinical pipeline and fast growing reported revenue, yet the share price has been hit hard in recent months. Is this a strong platform now trading at a reasonable valuation, or still too rich for the risks involved?
Preferred Price-to-Sales Multiple of 35.3x: Is it justified?
On the latest numbers, Nanjing Leads Biolabs trades on a P/S ratio of 35.3x, which looks expensive relative to its falling share price and recent weak returns.
The P/S multiple compares the market value of the business to its reported revenue and is often used for loss-making biotech groups where earnings are still negative. For Nanjing Leads Biolabs, investors are effectively paying 35.3 times its reported top line of CN¥213.224 million while the company is still reporting a net loss of CN¥266.958 million.
That rich tag does not sit in isolation. The stock is described as expensive versus the estimated fair P/S ratio of 15.7x, so the current valuation level is more than double the level the SWS model suggests the market could move towards if pricing lined up more closely with fundamentals. Relative to peers, the P/S ratio of 35.3x also screens as steep when set against both the Hong Kong Biotechs industry average of 10.3x and the peer group average of 12.8x. This points to very high expectations already reflected in the current HK$45.16 share price.
Explore the SWS fair ratio for Nanjing Leads Biolabs.
Result: Price-to-sales of 35.3x (OVERVALUED)
Still, the clinical-stage focus of Nanjing Leads Biolabs and its ongoing net loss of CN¥266.958 million leave investors exposed if trial results or funding conditions disappoint.
Find out about the key risks to this Nanjing Leads Biolabs narrative .
Another view on Nanjing Leads Biolabs valuation
A different yardstick tells a similar story. The SWS DCF model estimates Nanjing Leads Biolabs future cash flow value at HK$18.65 per share, while the market price is HK$45.16. That gap points to an expensive stock on this framework as well. Could expectations be running ahead of fundamentals?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Nanjing Leads Biolabs for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 180 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this combination of stretched valuation and clinical risk around Nanjing Leads Biolabs feels uneasy, consider acting quickly, examine the numbers yourself, and weigh both sides of the story through the 2 key rewards and 1 important warning sign .
Looking for more Nanjing Leads Biolabs investment ideas?
If Nanjing Leads Biolabs now feels finely balanced on risk versus reward, you could broaden your watchlist with a few focused stock baskets that target different drivers of potential returns.
-
Target potential future bargains by scanning a focused set of quality companies that look mispriced using the 180 high quality undervalued stocks .
-
Build more predictable income by reviewing steady payers highlighted in the 227 dividend fortresses .
-
Dial down portfolio stress by concentrating on financially robust businesses through the list of solid balance sheet and fundamentals (206 results) .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 9887.HK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
